RETATRUTIDE 10

 Classification: Novel synthetic peptide & Triple-Agonist (GLP-1 / GIP / Glucagon receptor agonist).  

 Mechanism of Action:

 GLP-1: Slows gastric emptying, suppresses appetite, improves glucose-dependent insulin secretion.  

 GIP: Enhances insulin sensitivity and fat metabolism while buffering nausea.  

 Glucagon: Increases basal energy expenditure and speeds up lipolysis (fat breakdown).  

 Primary Target Applications: Advanced metabolic research, dramatic body weight reduction, visceral fat loss, and blood glucose regulation.  

 Clinical Efficacy (Phase II/III Data): Demonstrates up to ~24% to 28%+ total body weight loss in trial subjects—outperforming single and dual agonists like semaglutide and tirzepatide.  

 Key Distinctions: Unlike earlier GLP-1/GIP peptides, the addition of the Glucagon receptor target actively boosts daily metabolic rate (energy expenditure) alongside appetite suppression.  

 Common Side Effects: Dose-dependent GI symptoms (nausea, mild diarrhea, constipation) and transient skin sensitivity (dysesthesia) during titration.

Not for human consumption. Research purposes only.